Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALK-001 in healthy volunteers
NCT02230228Phase 1Completed
- Sponsor
- Alkeus Pharmaceuticals, Inc.
- Start
- Apr 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of gildeuretinol in Stargardt disease (STGD) and age-related macular degeneration (AMD), sponsored by Alkeus Pharmaceuticals, Inc. Primary endpoint: Safety of 4-week daily dosing of ALK-001. Started Apr 2014; status: completed.
02
Drugs
gildeuretinol
03
Conditions
Stargardt disease (STGD)age-related macular degeneration (AMD)
Beyond the preview
Go deeper on NCT02230228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02230228.